日本語
IR LIBRARY

IR News

Kubota Pharmaceutical Holdings Co., Ltd.

2023

11/30
Notice on Determination of Details of Issuance of Stock Acquisition Rights (in Japanese)
11/21
Shinagawa Joshi Gakuin Participates in ZERO Diopter Project to Eradicate Myopia (in Japanese)
11/15
Notice on Issuance of Stock Acquisition Rights (in Japanese)
11/14
Quarterly Report for the third quarter of FY2023 (in Japanese)
11/14
Consolidated Financial Results for the Nine Months Ended September 30, 2023 (under IFRS)
11/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
10/30
Kubota Vision Announces Issuance of Patent
10/26
Japan's First Professional Gamer's College x ZERO Diopter Project to Support Students Who Turn "Love" into "Work" (in Japanese)
10/12
Kubota Vision Announces Issuance of Patents
10/02
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
09/25
Kubota Pharmaceutical Holdings Co., Ltd. Announces Notice of Establishment of Shareholder Benefit Program (in Japanese)
09/14
Kubota Pharmaceutical Holdings Co., Ltd. Announces Participation of the "i2.JP", Open Innovation Network by AstraZeneca (in Japanese)
09/07
Kubota Vision Announces Collaborative Research Agreement with China Medical University Hsinchu Hospital
09/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
08/31
Kubota Pharmaceutical Holdings Co., Ltd. to Present at Seminar for the Pacific Northwest Chapter of the Society for Information Display
08/30
Kubota Vision Announces Issuance of Patents
08/29
Kubota Pharmaceutical Holdings Co., Ltd. Announces Letter of Intent for Collaboration Opportunities with Sanming City, Fujian Province, China (in Japanese)
08/23
FY2023Q2 Financial Results Analyst Meeting presentation
08/22
Kubota Pharmaceutical Holdings Co., Ltd. Announces Distributor Agreement with Tenryo in Japan
08/21
Kubota Pharmaceutical Holdings Co., Ltd. Announces Initiating Business Verification Project with Rocket Studio, Inc. Using Kubota Glass and Microsoft HoloLens 2
08/10
Quarterly Report for the second quarter of FY2023 (in Japanese)
08/10
Consolidated Financial Results for the Six Months Ended June 30, 2023 (under IFRS)
08/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
07/21
Kubota Pharmaceutical Holdings Co., Ltd. to Present at the Refractive Surgery Update Seminar 2023 in Kyoto
07/06
Kubota Vision Announces Issuance of Patent
07/03
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
06/28
Kubota Vision Announces Issuance of Patent
06/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
05/12
Quarterly Report for the first quarter of FY2023 (in Japanese)
05/12
Consolidated Financial Results for the Three Months Ended March 31, 2023 (under IFRS)
05/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
04/24
Resolutions of the Ordinary General Meeting of Shareholders for the Fiscal Year 2022 (in Japanese)
04/24
Extraordinary Report (in Japanese)
04/19
Kubota Vision Announces Issuance of Patents
04/12
Kubota Vision Announces Issuance of Patent
04/05
Kubota Vision Announces Issuance of Patents
04/03
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
03/31
Business plan and matters related to high growth potential (in Japanese)
03/29
FY2022 Annual Security Report (in Japanese)
03/01
Notice of Partial Amendments to the Articles of Incorporation
03/01
Notice Concerning Personnel Changes of Directors and Executive Officers
03/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
02/21
FY2022 Financial Results Analyst Meeting presentation
02/14
Notice of Recognition of Financial Income, Financial Costs and Other Income (in Japanese)
02/14
Notice of Difference between Earnings Forecast and Actual Results (in Japanese)
02/14
Consolidated Financial Results for the Fiscal Year Ended December 31, 2022 (under IFRS)
02/01
Kubota Pharmaceutical Holdings Co., Ltd. Announces an Update to its Corporate Structure and Transition to a Company with an Audit and Supervisory Committee System
02/01
Kubota Vision Initiates Prospective Study Using Kubota Glass at Kagoshima Sonoda Eye Clinic and Plastic Surgery in Japan
02/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
01/10
Kubota Vision Initiates PBOS Clinical Study in Patients with Diabetic Macular Edema
01/04
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)

2022

12/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
11/24
Correction Extraordinary Report (in Japanese)
11/24
Notice on Determination of Details of Issuance of Stock Acquisition Rights (in Japanese)
11/11
Extraordinary Report (in Japanese)
11/11
Notice on Issuance of Stock Acquisition Rights (in Japanese)
11/11
Quarterly Report for the third quarter of FY2022 (in Japanese)
11/11
Kubota Pharmaceutical Holdings Co., Ltd. Announces Revision of Consolidated Revenue Forecast
11/11
Consolidated Financial Results for the Nine Months Ended September 30, 2022 (under IFRS)
11/01
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
10/31
Kubota Pharmaceutical Holdings Co., Ltd. Announces Changes to Contacting Company (in Japanese)
10/14
Notice of Large-scale Exercise of the 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
10/03
Kubota Vision Announces Positive Post Hoc Analysis from Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease
10/03
Monthly Update - The 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
09/29
Kubota Vision Announces Collaboration Agreement with Leading Diabetes Center
09/06
Kubota Vision Announces the Results of Clinical Study in Children Using Wearable Myopia Control Device based on Kubota Glass Technology
09/05
Notice Concerning Completion of Payment for the 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) by Third-Party Allotment (in Japanese)
08/25
FY2022Q2 Financial Results Analyst Meeting presentation
08/19
Notice Concerning Determination of Terms and Conditions for the 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) by Third-Party Allotment (in Japanese)
08/19
Correction: Notice Concerning Issuance of the 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) by Third-Party Allotment and Execution of Third-Party Allotment Agreement (in Japanese)
08/12
Notice Concerning Issuance of the 28th Stock Acquisition Rights (with Exercise Price Revision Clauses) by Third-Party Allotment and Execution of Third-Party Allotment Agreement (in Japanese)
08/12
Quarterly Report for the second quarter of FY2022 (in Japanese)
08/12
Consolidated Financial Results for the Six Months Ended June 30, 2022 (under IFRS)
08/12
Notice Concerning Change in Use of Funds for the 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
08/12
Kubota Vision Announces Top-Line Results from Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease
08/01
Kubota Vision Announces Kubota Glass Commercialization in Japan (in Japanese)
07/11
Notice Concerning Exercise and Completion of Exercise of the 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
07/08
Notice of Large-scale Exercise of the 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
07/07
Notice of Large-scale Exercise of the 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
07/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
06/27
Notice of Large-scale Exercise of the 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
06/24
Kubota Vision Announced End of Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease
06/21
Notice of Large-scale Exercise of the 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
06/20
Kubota Vision Announces Kubota Glass Commercialization in the U.S.
06/13
Kubota Vision Announces the Registration with the US FDA for Kubota Glass
06/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
05/13
Quarterly Report for the first quarter of FY2022 (in Japanese)
05/13
Supporting Document for the first quarter of FY2022 (in Japanese)
05/13
Consolidated Financial Results for the Three Months Ended March 31, 2022 (under IFRS)
05/02
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
04/25
Resolutions of the Ordinary General Meeting of Shareholders for the Fiscal Year 2021 (in Japanese)
04/25
Extraordinary Report (in Japanese)
04/13
Independent Director Report Submitted to Tokyo Stock Exchange (in Japanese)
04/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
03/29
FY2021 Annual Security Report (in Japanese)
03/15
Notice on Issuance of Stock Acquisition Rights (in Japanese)
03/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
02/18
FY2021 Financial Results Analyst Meeting presentation
02/15
Correction of Consolidated Financial Results for the Fiscal Year Ended December 31, 2020 (under IFRS) (in Japanese)
02/14
Consolidated Financial Results for the Fiscal Year Ended December 31, 2021 (under IFRS)
02/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
01/04
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)

2021

12/16
Kubota Pharmaceutical Holdings Co., Ltd. Announces Revision of Consolidated Earnings Forecast
12/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
11/12
Quarterly Report for the third quarter of FY2021 (in Japanese)
11/12
Business plan and matters related to high growth potential (in Japanese)
11/12
Supporting Document for the third quarter of FY2021 (in Japanese)
11/12
Consolidated Financial Results for the Nine Months Ended September 30, 2021 (under IFRS)
11/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
10/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
09/21
Board Resolution on Selecting Tokyo Stock Exchange's New "Growth Market" Segment (in Japanese)
09/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
08/24
FY2021Q2 Financial Results Analyst Meeting presentation
08/12
Quarterly Report for the second quarter of FY2021 (in Japanese)
08/12
Consolidated Financial Results for the Six Months Ended June 30, 2021 (under IFRS)
08/02
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
07/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
06/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
05/13
Quarterly Report for the first quarter of FY2021 (in Japanese)
05/13
Supporting Document for the first quarter of FY2021 (in Japanese)
05/13
Consolidated Financial Results for the Three Months Ended March 31, 2021 (under IFRS)
05/06
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
04/26
Resolutions of the Ordinary General Meeting of Shareholders for the Fiscal Year 2020 (in Japanese)
04/26
Extraordinary Report (in Japanese)
04/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
03/29
FY2020 Annual Security Report (in Japanese)
03/18
Notice on Issuance of Stock Acquisition Rights (in Japanese)
03/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)
02/24
FY2020 Financial Results Analyst Meeting - recorded video presentation (in Japanese)
02/22
FYE2020 Financial Results Analyst Meeting presentation
02/12
Consolidated Financial Results for the Fiscal Year Ended December 31, 2020 (under IFRS)
02/01
Monthly Update - The 25th Stock Acquisition Rights (with Exercise Price Revision Clauses) (in Japanese)

2020

08/25
FYE2020Q2 Financial Results Analyst Meeting presentation
02/25
FYE2019 Financial Results Analyst Meeting presentation

2019

08/27
FYE2019Q2 Financial Results Analyst Meeting presentation
03/06
FYE2018 Financial Results Analyst Meeting presentation

2018

11/14
FYE2018Q3 Financial Results presentation
08/21
FYE2018Q2 Financial Results Analyst Meeting presentation
05/17
FYE2018Q1 Financial Results presentation
02/21
FYE2017 Financial Results Analyst Meeting presentation

2017

11/22
FYE2017Q3 Financial Results Analyst Meeting presentation
08/23
FYE2017Q2 Financial Results Analyst Meeting presentation
05/18
FYE2017Q1 Financial Results Analyst Meeting presentation
02/21
FYE2016 Financial Results Analyst Meeting presentation

2016

11/15
FYE2016Q3 Financial Results Analyst Meeting presentation
10/21
2016 Annual Event for Shareholders
08/24
FYE2016Q2 Financial Results Analyst Meeting presentation
05/10
FYE2016Q1 Financial Results Analyst Meeting presentation
03/29
FYE2015 Financial Results Analyst Meeting presentation

2015

11/24
FYE2015 3rd Quarter Financial Results Analysts Meeting presentation
08/26
FYE2015 2nd Quarter Financial Results Analysts Meeting presentation
07/01
2015 Annual Event for Shareholders
05/20
Investor Presentation Dated May 20, 2015

2014

11/18
FY2014 3rd Quarter Financial Results Analysts Meeting presentation
09/27
BioCentury "Newsmakers in the Biotech Industry" presentation
08/21
FYE2014 2nd Quarter Financial Results Analysts Meeting presentation
06/11
2014 Annual Shareholder Event
05/21
FYE2014 1st Quarter Financial Results Analysts Meeting presentation
05/07
2014 Proxy Statement
05/07
2013 Annual Report to Stockholders

Acucela Inc.